Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective

Basit Öğe Kaydı
dc.authoridElkeraie, Ahmed/0000-0002-0305-2290
dc.authorwosidalghamdi, saeed/ADH-7799-2022
dc.contributor.authorElkeraie, Ahmed Fathi
dc.contributor.authorAl-Ghamdi, Saeed
dc.contributor.authorAbu-Alfa, Ali K.
dc.contributor.authorAlotaibi, Torki
dc.contributor.authorAlsaedi, Ali Jasim
dc.contributor.authorAlsuwaida, Abdulkareem
dc.contributor.authorArici, Mustafa
dc.date.accessioned2024-05-19T14:40:04Z
dc.date.available2024-05-19T14:40:04Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractChronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter -2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD.en_US
dc.description.sponsorshipAstraZeneca FZ, LLCen_US
dc.description.sponsorshipThe preparation of this consensus manuscript and funding of the journal's article processing charges were supported by AstraZeneca FZ, LLC. All authors had full access to all the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analyses.en_US
dc.identifier.doi10.2147/IJNRD.S430532
dc.identifier.endpage16en_US
dc.identifier.issn1178-7058
dc.identifier.pmid38196830en_US
dc.identifier.scopus2-s2.0-85182400699en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org10.2147/IJNRD.S430532
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4900
dc.identifier.volume17en_US
dc.identifier.wosWOS:001140804800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofInternational Journal of Nephrology and Renovascular Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectChronic Kidney Diseaseen_US
dc.subjectNephrology Referralen_US
dc.subjectScreeningen_US
dc.subjectSodium-Glucose Cotransporter-2 Inhibitorsen_US
dc.titleImpact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspectiveen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu